“Jakob is 2 years old. He has a deadly disease. But drug companies won't give him the cure — because they won't make a big enough profit.”
That was the headline yesterday on a matter involving a $43 million investment by California taxpayers, a London-based company, the University of California, the Golden State’s stem cell agency and a rare genetic imm…
Keep reading with a 7-day free trial
Subscribe to The California Stem Cell Report to keep reading this post and get 7 days of free access to the full post archives.
